Translational and phase I evaluation of AZD0292, a novel, half-life extended anti-Pseudomonal Psl-PcrV bispecific monoclonal antibody

Clicks: 19
ID: 331984
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #398 of 503 articles by views in The Journal of infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 503 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Chronic Pseudomonas aeruginosa airway colonization in bronchiectasis (BE) is associated with frequent exacerbations. Bispecific antibody AZD0292, targeting P. aeruginosa Psl and PcrV, was engineered from gremubamab with a Fc N3Y substitution to extend half-life and is being developed to reduce exacerbations in BE with chronic P. aeruginosa colonization. Methods Preclinical studies assessed opsonophagocytic killing and anti-cytotoxicity assays, repeat-dose toxicology with ex vivo pharmacodynamic analyses in cynomolgus monkeys, and pharmacokinetics in human FcRn transgenic mice. In Phase I, healthy adults were randomized to receive a single dose of AZD0292 (n =24) or placebo (n = 8) in 4 cohorts (100-2,000 mg) and followed for 61 days or 161 days in cohort 4. Endpoints included safety, pharmacokinetics, immunogenicity, and exploratory cytokine/complement assessments. Results AZD0292 demonstrated comparable functional activity to gremubamab, an approximately 55% lower clearance in transgenic mice, and retained anti-P. aeruginosa activity in cynomolgus monkey serum after repeated dosing. In Phase I, AZD0292 was generally well tolerated. Mild/moderate infusion-related reactions occurred only at higher doses and were managed with routine clinical measures. Transient cytokine increases were observed after dosing, with no meaningful complement activation. Pharmacokinetics were approximately dose-dependent but slightly less than dose-proportional across 100-2,000 mg. Geometric mean half-life ranged from 24 to 47 days, though estimates are provisional given small cohort sizes and limited follow-up. No treatment-emergent anti-drug antibodies were detected. Conclusions These results support further clinical development of AZD0292 for reduction of exacerbations in BE with chronic P. aeruginosa colonization, with pharmacokinetics requiring confirmation in the target patient population.
Reference Key
openalex_W7221105837 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Engin Baturcam, Camille Riff, Antonio DiGiandomenico, Fred Reid, Liesel D'silva, Margaret Kehl, John Kim, Mun Mun Patnaik, Ashley Elaine Keller, Rikard Pehrson, Sanna Rosengren, Jieqiang Zhou, Marianna Stamou, Huixia Zhang, Patricia C. Ryan, Richard Baldry, Gabriel Abreu, Mushtaq Husain, Karen Cartwright, Isabelle de Mendez, Ron Goldwater, Wayne Brailsford, Rod Hughes
Are you one of these authors? Claim your profile
Journal The Journal of infectious diseases
Year 2026
DOI
10.1093/infdis/jiag500
URL
https://doi.org/10.1093/infdis/jiag500
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.